ATHE
Price
$5.06
Change
+$0.12 (+2.43%)
Updated
Sep 2, 04:36 PM (EDT)
Capitalization
81.22M
EYPT
Price
$11.72
Change
+$0.16 (+1.38%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
797.49M
57 days until earnings call
Interact to see
Advertisement

ATHE vs EYPT

Header iconATHE vs EYPT Comparison
Open Charts ATHE vs EYPTBanner chart's image
Alterity Therapeutics
Price$5.06
Change+$0.12 (+2.43%)
Volume$500
Capitalization81.22M
EyePoint Pharmaceuticals
Price$11.72
Change+$0.16 (+1.38%)
Volume$18.19K
Capitalization797.49M
ATHE vs EYPT Comparison Chart in %
Loading...
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHE vs. EYPT commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Buy and EYPT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ATHE: $4.94 vs. EYPT: $11.57)
Brand notoriety: ATHE and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 14% vs. EYPT: 74%
Market capitalization -- ATHE: $81.22M vs. EYPT: $797.49M
ATHE [@Biotechnology] is valued at $81.22M. EYPT’s [@Biotechnology] market capitalization is $797.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than ATHE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHE’s TA Score shows that 3 TA indicator(s) are bullish while EYPT’s TA Score has 3 bullish TA indicator(s).

  • ATHE’s TA Score: 3 bullish, 4 bearish.
  • EYPT’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both ATHE and EYPT are a bad buy in the short-term.

Price Growth

ATHE (@Biotechnology) experienced а -1.59% price change this week, while EYPT (@Biotechnology) price change was -2.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($797M) has a higher market cap than ATHE($81.2M). EYPT YTD gains are higher at: 55.302 vs. ATHE (49.245). ATHE has higher annual earnings (EBITDA): -19.88M vs. EYPT (-172.05M). EYPT has more cash in the bank: 256M vs. ATHE (4.54M). ATHE has less debt than EYPT: ATHE (106K) vs EYPT (21.8M). EYPT has higher revenues than ATHE: EYPT (51.9M) vs ATHE (0).
ATHEEYPTATHE / EYPT
Capitalization81.2M797M10%
EBITDA-19.88M-172.05M12%
Gain YTD49.24555.30289%
P/E RatioN/AN/A-
Revenue051.9M-
Total Cash4.54M256M2%
Total Debt106K21.8M0%
FUNDAMENTALS RATINGS
ATHE vs EYPT: Fundamental Ratings
ATHE
EYPT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3837
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (58) in the Pharmaceuticals Major industry is in the same range as ATHE (86) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.

EYPT's Profit vs Risk Rating (84) in the Pharmaceuticals Major industry is in the same range as ATHE (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.

EYPT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ATHE (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as ATHE (38) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.

EYPT's P/E Growth Rating (18) in the Pharmaceuticals Major industry is significantly better than the same rating for ATHE (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than ATHE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATHEEYPT
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 5 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
89%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
84%
Advances
ODDS (%)
Bullish Trend 13 days ago
72%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 5 days ago
79%
Bearish Trend 5 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMSHX27.120.01
+0.04%
Franklin Mutual Shares R6
RLECX21.61-0.07
-0.32%
Russell Inv US Small Cap Equity C
IVAEX24.22-0.09
-0.37%
Macquarie Asset Strategy Fund Cl I
SCAUX11.74-0.05
-0.42%
Invesco Income Advantage U.S. Fund A
SRIGX14.13-0.07
-0.49%
Gabelli SRI AAA

ATHE and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHE
1D Price
Change %
ATHE100%
-1.63%
EYPT - ATHE
54%
Loosely correlated
-0.26%
TECX - ATHE
35%
Loosely correlated
-0.12%
GHRS - ATHE
31%
Poorly correlated
-2.46%
GLMD - ATHE
31%
Poorly correlated
-7.97%
CVM - ATHE
30%
Poorly correlated
+12.03%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-0.26%
OCUL - EYPT
65%
Loosely correlated
-2.48%
LYRA - EYPT
58%
Loosely correlated
-0.71%
ATHE - EYPT
54%
Loosely correlated
-1.63%
BEAM - EYPT
53%
Loosely correlated
-2.91%
RXRX - EYPT
53%
Loosely correlated
-3.39%
More